The functional anatomy of noradrenergic neurons in Parkinson's disease

Functional Neurology

Volumn 14, Issue 2, 1999, Pages 97-109

  Soldani, Paola ^a   Fornai, Francesco ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

DSP 4; Locus coeruleus; MPTP; Norepinephrine; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; 4 AMINOBUTYRIC ACID; ACETYLCHOLINE; DOPAMINE; NEUROTRANSMITTER; NORADRENALIN; SEROTONIN;

ARTICLE; BRADYKINESIA; BRAIN REGION; DOSE RESPONSE; HUMAN; LOCUS CERULEUS; NEUROTRANSMISSION; NORADRENERGIC NERVE; NORADRENERGIC SYSTEM; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; RIGIDITY; TREMOR;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; LOCUS COERULEUS; NERVE DEGENERATION; NEURAL PATHWAYS; NEURONS; NOREPINEPHRINE; PARKINSON DISEASE; RECEPTORS, ADRENERGIC, ALPHA;

EID: 0032837991     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Forno LS. Neuropathology of Parkinson's Disease. J Neuropathol Exp Neurol 1996;55:259-272
2. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-375.
3. Gerlach M, Riederer P. The pathophysiological basis of Parkinson's disease. In: Szlenyi I ed Series of New Drugs, Vol. 1, Inhibitors of Monoamine Oxidase B. Basel; Birkhauser 1993:25-50
4. Jankovic J. Pathophysiology and clinical assessment of motor symptoms in Parkinson's Disease In: Koller WC ed Handbook of Parkinson's Disease. New York; Dekker 1992:129-157.
5. Brodal A. Neurological Anatomy in Relation to Clinical Medicine. 3rd edition, Oxford; Oxford University Press 1981
6. German DC, Walker BS, Manaye K, Smith WK, Woodward DJ, North AJ. The human locus coeruleus: computer reconstruction of cellular distribution. J Neurosci 1988;8:1776-1788
7. Chan-Palay V, Asan E. Quantification of catecholamine neurons in the locus coeruleus in the human brain of normal young and older adults and in depression. J Comp Neurol 1989;287:357-372
8. Linvall O, Stenevi U. Dopamine and noradrenaline neurons projecting to the septal area in the rat. Cell Tissue Res 1978;190:383-407
9. Alvord EC, Forno LS. Pathology. In: Koller WC ed Handbook of Parkinson's Disease, New York; Dekker 1992:258-259
10. Tretiakoff C. Contribution à l'etude de l'Anatomie pathologique du Locus Niger de Soemmering avec quelques déductions rélatives á la pathogenie des troubles du tonus musculaire de la maladie de Parkinson. Thése de Paris, 1919
11. Beheim-Schwarzbach D. Uber Zelleib-Veranderungen im Nucleus Coeruleus bei Parkinson Symptomen. J Nerv Ment Dis 1952;116:619-632
12. German DC, Manaye KF, White CL, et al. Disease-specific pattern of locus coeruleus cell loss. Ann Neurol 1992;32:667-676
13. Forno LS, Alvord EC Jr. The pathology of parkinsonism, Part I. Some new observations and correlations. J Comp Neurol 1971;8:120-130
14. Bertrand E, Lechowicz W, Szpak GM, Dynecki J. Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease. Folia Neuropathol 1997;35:80-86.
15. Chan-Palay V, Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer's type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 1989;287:373-392.
16. Gaspar P, Duyckaerts C, Alvarez C, Javoy-Agid F, Berger B. Alterations of dopaminergic and noradrenergic innervations in motor cortex of Parkinson's disease. Ann Neurol 1991;30:365-374
17. Ehringer H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr verhalten bei Erkrankungen des Extrapyramidalen Systems. Klin Wochenschr 1960;38:1236-1239
18. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1986;45:19-34
19. Hornykiewicz O, Pifl C. The validity of the MPTP primate model for neurochemical pathology of idiopathic Parkinson's disease. In: Briley M, Marien M eds Noradrenergic mechanisms in Parkinson's disease. Boca Raton; CRC Press 1994:59-71
20. Kish SJ, Shannak KS, Rajput AH, Gilbert JJ, Hornykiewicz O. Cerebellar norepinephrine in patients with Parkinson's disease and control subjets. Arch Neurol 1984; 41:612-614
21. Scatton B, Dennis T, L'Hereux R, Monfort J, Duyckaerts C, Javoy-Agid F. Degeneration of noradrenergic and serotoninergic but not dopaminergic neurons in the lumbar spinal cord of parkinsonian patients. Brain Res 1986;380:181-185
22. Farley IJ, Hornykiewicz O. Noradrenaline in subcortical brain regions of patients with Parkinson's disease and control subjects. In: Birkmayer W, Hornykiewicz O eds Advances in Parkinsonism. Basel; Editiones Roche 1976:178-185
23. Scatton B, Javoy-Agid F, Roquier L, Dubois B, Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 1983;275:321-328
24. Birkmayer W, Danielczyk W, Riederer P. Symptoms and side effects in the course of Parkinson's disease. New Trends in Clinical Neuropharmacology 1987;1:37-48
25. Bondareff W, Mountjoy CQ, Roth M. Loss of neurons of origin of the adrenergic projection to the cerebral cortex (nucleus locus coeruleus) in senile dementia. Neurology 1982;32:165-168
26. Dooneief G, Mirabello E, Bell K, Marder K, Stern Y, Mayeux R. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 1992;49: 305-307
27. Zubenko GS, Moossy J, Kopp U. Neurochemical correlates of major depression and primary dementia. Arch Neurol 1990; 47:209-214
28. Goto S, Hirano A. Catecholaminergic neurons in the parabrachial nucleus of normal individuals and patients with idiopathic Parkinson's disease. Ann Neurol 1991;30: 192-196
29. Mizuno Y, Kondo T, Mori H. Various aspects of motor fluctuations and their management in Parkinson's disease. Neurology 1994;44:S29-S34
30. Seniuk NA, Tatton WG, Greenwood CE. Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res 1990;27:7-20
31. Pifl CH, Schingnitz G, Hornykiewicz O. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrydine on the regional distribution of the monoamines in rhesus monkeys. Neuroscience 1991;44:591-605
32. Mavridis M, Degryse AD, Lategan AJ, Marien MR, Colpaert FC. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 1991; 41:507-523
33. Marien M, Briley M, Colpaert F. Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Eur J Pharmacol 1993;236: 487-489
34. Bing G, Zhang Y, Watanabe Y, McEwen BS, Stone EA. Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res 1994;668:261-265
35. Reading PJ, Dunnett SB. 6-hydroxydopamine lesions of nigrostriatal neurons as an animal model of Parkinson's disease. In: Woodruff ML, Nonneman AJ eds. Toxins-induced Models of Neurological Disorders. New York; Plenum Press 1994:89-119
36. Lidbrink P, Jonsson G. Noradrenaline nerve terminals in the cerebral cortex: effects on noradrenaline uptake and storage following axonal lesion with 6-hydroxydopamine. J Neurochem 1974;22:617-626
37. Ross SB, Renyi AL. On the long-lasting inhibitory effect of N-(-2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on the active uptake of noradrenaline. J Pharm Pharmacol 1976;28:458-459
38. Fornai F, Bassi L, Torracca MT, Scalori V, Corsini GU. Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice. Eur J Pharmacol 1995;283:99-102
39. Follesa P, Mocchetti I. Regulation of basic fibroblast growth factor and nerve growth factor mRNA by beta-adrenergic receptor activation and adrenal steroids in rat central nervous system. Mol Pharmacol 1993;43: 132-138
40. Otto D, Unsicker K. Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice. J Neurosci 1990;10:1912-1921
41. Seiden LS, Fischman MW, Schuster CR. Long-term methamphetamine induced changes in brain catecholamine in tolerant rhesus monkeys. Drug Alcohol Depend 1975;1:215-219
42. Fornai F, Torracca MT, Bassi L, D'Errigo DA, Scalori V, Corsini GU. Norepinephrine loss selectively enhances chronic nigrostriatal dopamine depletion in mice and rats. Brain Res 1996;735:349-353.
43. Speciale SG, Liang CL, Sonsalla PK, Edwards RH, German DC. The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain vesicular monoamine transporter. Neuroscience 1998;84:1177-1185
44. Melamed E, Rosenthal J, Cohen O, Globus M, Uzzan A. Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP. Eur J Pharmacol 1985;116:179-181
45. Fornai F, Alessandrì MG, Torracca MT, Bassi L, Corsini GU. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions. J Pharmacol Exp Ther 1997;283: 100-107
46. Turski L, Bressler K, Rettig KJ, Loshmann PA, Wachtel H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991;349:414-418
47. Kamisaki Y, Hamahashi T, Hamada T, Maeda K, Itoh T. Presynaptic inhibition by clonidine of neurotransmitter amino acid release in several brain regions. Eur J Pharmacol 1992;217:57-63
48. Fornai F, Alessandrì MG, Fascetti F, Vaglini F, Corsini GU. Clonidine suppresses 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced reductions of striatal dopamine and tyrosine hydroxylase activity in mice. J Neurochem 1995;65:704-709
49. Fornai F, Giorgi FS, Alessandrì MG, Giusiani M, Corsini GU. Effects of pretreatment with DSP-4 on methamphetamine-induced striatal dopamine losses and pharmacokinetics. J Neurochem 1999;72:777-784
50. Andèn N-E, Grabowska M. Pharmacological evidence for a stimulation of dopamine neurons by noradrenaline neurons in the brain. Eur J Pharmacol 1976;39:275-282
51. O'Dell SJ, Weihmuller FB, Marshall JF. Methamphetamine-induced dopamine overflow and injury to striatal dopamine terminals: attenuation by dopamine D1 and D2 antagonists. J Neurochem 1993;60: 1792-1799
52. Mason ST, Fibinger HC. Regional topography within noradrenergic locus coeruleus as revealed by retrograde transport of horseradish peroxidase. J Comp Neurol 1979;187:703-724
53. Fornai F, Bassi L, Torracca MT, Alessandri MG, Scalori V, Corsini GU. Region-and neurotransmitter-dependent species and strain differences in DSP-4-induced monoamine depletion in rodents. Neurodegeneration 1996;5:241-249.